CA2779413A1 - Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth - Google Patents

Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth Download PDF

Info

Publication number
CA2779413A1
CA2779413A1 CA2779413A CA2779413A CA2779413A1 CA 2779413 A1 CA2779413 A1 CA 2779413A1 CA 2779413 A CA2779413 A CA 2779413A CA 2779413 A CA2779413 A CA 2779413A CA 2779413 A1 CA2779413 A1 CA 2779413A1
Authority
CA
Canada
Prior art keywords
difficile
group
associated disease
subject
con
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2779413A
Other languages
English (en)
French (fr)
Inventor
Joseph Sorg
Abraham L. Sonenshein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of CA2779413A1 publication Critical patent/CA2779413A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2779413A 2008-11-03 2009-11-02 Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth Abandoned CA2779413A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11074708P 2008-11-03 2008-11-03
US61/110,747 2008-11-03
US12283508P 2008-12-16 2008-12-16
US61/122,835 2008-12-16
US15013609P 2009-02-05 2009-02-05
US61/150,136 2009-02-05
PCT/US2009/005929 WO2010062369A2 (en) 2008-11-03 2009-11-02 Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth

Publications (1)

Publication Number Publication Date
CA2779413A1 true CA2779413A1 (en) 2010-06-03

Family

ID=42226300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2779413A Abandoned CA2779413A1 (en) 2008-11-03 2009-11-02 Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth

Country Status (6)

Country Link
US (2) US9340569B2 (cg-RX-API-DMAC7.html)
EP (1) EP2367839A4 (cg-RX-API-DMAC7.html)
JP (1) JP5620392B2 (cg-RX-API-DMAC7.html)
AU (1) AU2009320350B2 (cg-RX-API-DMAC7.html)
CA (1) CA2779413A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010062369A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020035720A1 (en) 2018-08-17 2020-02-20 Universidad Andrés Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile.
WO2023079335A1 (en) 2021-11-03 2023-05-11 Universidad Andrés Bello Composition based on nystatin and vancomycin nanoparticles for the treatment of clostridioides difficile infection and prevention of recurrence

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
EP3628161B1 (en) 2012-11-23 2023-04-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2899926C (en) 2013-02-04 2025-11-18 Seres Therapeutics, Inc. DIGESTIVE TUBE FILLING COMPOSITIONS
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
WO2015076788A1 (en) 2013-11-19 2015-05-28 The Texas A&M University System Muricholic acid-based compounds as inhibitors of clostridium difficile spore germination
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CA2949232A1 (en) * 2014-05-19 2015-11-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
GB201421071D0 (en) * 2014-11-27 2015-01-14 Univ Aston Compound for treating clostridium difficile
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
IL277648B2 (en) * 2015-11-03 2023-04-01 Brigham & Womens Hospital Inc Medical microbiota for the treatment and/or prevention of food allergy
CA3019732A1 (en) * 2016-04-05 2017-10-12 Nch Corporation Nutrient rich germinant composition and spore incubation method
CN111212655A (zh) 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法
KR102323783B1 (ko) * 2017-09-22 2021-11-09 주식회사 고바이오랩 클로스트리디움 디피실레(Clostridium difficile) 성장 억제효과를 갖는 클로스트리디움 신덴스 균주
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
TW202021595A (zh) 2018-08-10 2020-06-16 德商菲尼克斯製藥股份有限公司 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物
WO2020260558A1 (en) 2019-06-27 2020-12-30 Phenex Pharmaceuticals Ag 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
EP4011899A4 (en) * 2019-08-06 2022-09-28 Huang, Qiang DEOXYCHOLIC ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP4092103A4 (en) * 2020-01-16 2024-05-15 Keio University PROCESS FOR PRODUCING BILE ACIDS
AU2021220800A1 (en) 2020-02-10 2022-07-07 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
WO2023105494A1 (en) 2021-12-10 2023-06-15 Universidade Do Porto Cationic steroid compounds, method of obtaining thereof, formulations comprising thereof and their uses
CN120905091A (zh) * 2025-09-30 2025-11-07 北京常友生物科技有限公司 大肠埃希氏菌yc49及其协同拟杆菌在抑制艰难梭菌中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3708510A (en) * 1970-09-03 1973-01-02 Merck & Co Inc Amides of cholanic acid,cholenic acid,and choladienic acid
JPS62175497A (ja) 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd 胆汁酸誘導体およびその製造法
JPH0749438B2 (ja) * 1990-10-31 1995-05-31 東京田辺製薬株式会社 タウリン抱合型胆汁酸の精製方法
DE19645044A1 (de) * 1996-10-31 1998-05-07 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute
IL123998A (en) * 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US7247299B2 (en) 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
AU2007230991A1 (en) * 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
US20080254010A1 (en) * 2007-03-12 2008-10-16 Joseph Myron Sasser Controlling Clostridium difficile-Associated Disease in the Gastrointestinal Tract

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020035720A1 (en) 2018-08-17 2020-02-20 Universidad Andrés Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile.
WO2023079335A1 (en) 2021-11-03 2023-05-11 Universidad Andrés Bello Composition based on nystatin and vancomycin nanoparticles for the treatment of clostridioides difficile infection and prevention of recurrence

Also Published As

Publication number Publication date
AU2009320350B2 (en) 2015-09-24
WO2010062369A2 (en) 2010-06-03
JP2012507521A (ja) 2012-03-29
US20110280847A1 (en) 2011-11-17
WO2010062369A3 (en) 2010-10-14
US9340569B2 (en) 2016-05-17
EP2367839A2 (en) 2011-09-28
AU2009320350A1 (en) 2010-06-03
US20170056419A1 (en) 2017-03-02
JP5620392B2 (ja) 2014-11-05
EP2367839A4 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
AU2009320350B2 (en) Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth
USRE49949E1 (en) Reducing risk of contracting clostridium-difficile associated disease
AU2021218228B2 (en) Oxysterols and methods of use thereof
WO2019036510A1 (en) COMPOSITIONS AND METHODS FOR TREATING CHOLESTATIC DISEASE
US20200262865A1 (en) Compositions and methods for treating clostridium associated diseases
EP3965748A1 (en) Small molecule modulators of gut bacterial bile acid metabolism
EP0538192B1 (de) Neue 17beta-substituierte Aza-androstan-Derivate
GOLDMAN Role of the intestinal microflora
CN113874375A (zh) 用于治疗狂犬病的环状酰胺化合物及其方法
WO2015076788A1 (en) Muricholic acid-based compounds as inhibitors of clostridium difficile spore germination
Sharma et al. Studies on the Importance of the 7α-, and 12α-hydroxyl groups of N-Aryl-3α, 7α, 12α-trihydroxy-5β-cholan-24-amides on their Antigermination Activity Against a Hypervirulent Strain of Clostridioides (Clostridium) difficile
WO2018237268A1 (en) Novel antibacterial compounds and methods of making and using same
US20210323995A1 (en) Isolithocholic acid or isoallolithocholic acid and deuterated derivatives thereof for preventing and treating clostridium difficile-associated diseases
Sharma et al. 5, 6-Fused Heterocycle Cholate Derivatives as Spore Germination Inhibitors of Clostridioides difficile
MAEDA et al. Effects of aluminium-containing antacid on bioavailability of ofloxacin following oral administration of pivaloyloxymethyl ester of ofloxacin as prodrug
US10011589B2 (en) Treatments for gastrointestinal conditions
WO2020260558A1 (en) 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases
Xia et al. Targeted inhibition of gut bacterial β-glucuronidases by octyl gallate alleviates mycophenolate mofetil-induced gastrointestinal toxicity
MXPA04009429A (es) Derivados de esteroides de poliamina ramificada.
CN117897148A (zh) 不饱和羟肟酸衍生物及其用于治疗和预防氨相关疾病或病症的用途
AU2015287695B2 (en) N- (hydrophobe-substituted) vancosaminyl [Ψ[C(=NH) NH] Tpg4] vancomycin and [Ψ[CH2NH] Tpg4] vancomycin
Quayle Preparation of dual-action germinant-biocide smart polymer and soluble agent for the elimination of c. difficile spores
WO2004016580A2 (fr) Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
JP2022091476A (ja) 新規含窒素三環性骨格化合物およびその使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141027

FZDE Dead

Effective date: 20161102